Term
|
Definition
DOC for >65 y Parkinson's
Side Effects: Dyskinesias, On-off motor
MOA: inhibits decarboxylation of peripheral levodopa.
In presence of Carbidopa, crosses blood-brain barrier, is carboxylated into dopamine |
|
|
Term
|
Definition
<65 y Parkinson's
Side Effects: Confusion, ankle swelling
MOA: dopamine released from remaining intact dopaminergic terminals in substantia nigra |
|
|
Term
Pramipexole or Ropinarole |
|
Definition
<65 monotherapy Parkinson's; advanced pt adjunct to L-dopa
Side Effects: postural hypotension, hallucination, drowsiness (esp elderly)
MOA: directly stimulate dopamine receptors |
|
|
Term
|
Definition
Parkinson's, adjunct to L-dopa
Side Effects: GI, dyskinesias
MOA: inhibit plasma COMT(catechol-O methyl tranferase) enzyme--> prolongs T 1/2 of Levodopa. |
|
|
Term
|
Definition
adjunct to L-dopa
Side Effects: GI, dyskinesias, elevation of liver enzymes (seldome used, must monitor serial LFT's)
MOA: COMT inhibitor |
|
|
Term
|
Definition
young, mild Parkinson's: tremor, drooling
Side Effects: anticholinergic S/E=dry mouth, cognitive changes
MOA: antimuscarinic (prevents drooling) |
|
|
Term
Opioids (see 4/10 Medical Letter)
morphine, codeine, hydrocodone, oxycodone, heroin |
|
Definition
moderate to severe pain; postoperative med; adjunct for anaesthesia; some have antussive, antidiarrheal effects
AVOID in case of ill-defined chronic pain.
Side effects: addiction, constipation; overdose: coma, respiratory depression, miosis ("pinpoint pupils"); hypotension, decreased bowel sounds (acute: nausea and vomiting)
MOA: agonists at mu, delta, and kappa opioid receptors; primarily through Gi/Go proteins to hyperpolarize neurons and inhibit neurotransmitter release.
|
|
|
Term
|
Definition
opiod overdose
side effects: severe withdrawal if physically dependent
MOA: opioid antagonist |
|
|
Term
fentanyl (also meperidine, propoxyphene, tramadol, methadone, remifentanil) |
|
Definition
synthetic opioid agonist
fentanyl patch: for systemic pain, slow release
Side Effects: meperidine--excessive doses can lead to seizures from excessive accumulation of metabolites (esp if renal function impaired) |
|
|
Term
buprenorphine, nalbuphine |
|
Definition
partial agonist or mixed agonist/antagonist |
|
|
Term
|
Definition
to reverse respiratory and CNS depression in suspected overdose
MOA: displaces opioid narcotics from receptor sites |
|
|
Term
|
Definition
for opioid addiction and alcoholism (binge drinking, bulimia)
MOA: longer acting bioavailable opioid antagonist |
|
|
Term
diphenoxylate, loperamide |
|
Definition
antidiarrheal agent
MOA: opioid-related |
|
|
Term
lidocaine, procaine, bupivicaine, cocaine (ENT):
need DURATION OF ACTION |
|
Definition
local anaesthesia (dental extraction, suturing), spinal anesthesia, nerve blocks
MOA: block sodium channels, which prevents generation and conduction of nerve impulses
Combo with vasoconstrictors: epinephrine, phenylephrine, prolongs duration of action
Lidocaine: widely used, infiltration, prolonged by vasoconstrictors
Procaine: action is transient, allergic response likely (PABA)
Bupivicaine: injectable, long duration (binds to plasma proteins)
Cocaine: naturally occuring from Eythroxylon coca--can cause CNS depression and death (respiratory) following use. Blocks uptake of catecholamines |
|
|
Term
Guidelines for Epilepsy (AOA competencies) |
|
Definition
1) Know which drugs for which type of seizure (ex: phenytoin makes absence seizures worse)
2) Medical Letter: phenytoin no longer DOC for tonic-clonic or partial seizures
3) Treatment of epilepsy should begin with single drug
4) Difficult to control patients should be seen by a neurologist
|
|
|
Term
|
Definition
DOC for generalized TONIC-CLONIC (Grand Mal) seizure
(mood stabilization effect)
DOC for ABSENCE (Petit Mal) seizure
Side Effects: nausea/vomiting common (depakote enteric coated=better, also take with food, slow titration); weight gain relatively common; serious effects--uncommon--unexplained heptatoxicity esp <2 y (monitor liver function tests)
MOA: may increase GABA in brain. |
|
|
Term
lamotrigine (synergy? with valproate) |
|
Definition
DOC for generalized TONIC-CLONIC (Grand Mal)
DOC for ATYPICAL ABSENCE, MYOCLONIC, ATONIC
some adults: monotherapy
children >2 and adults: adjunct for partial seizures
Side Effects: rash (Stevens-Johnsons' Syndrome: severe, diffuse, involvment of mucosal surfaces). Risk of rash high if hi dose, dose increased too fast, or given w/ valproate. discontinue at first appearance of rash.
MOA: ?
|
|
|
Term
|
Definition
DOC for TONIC-CLONIC (Grand Mal)
DOC for PARTIAL, including secondary generalized seizures
DOC for ATYPICAL ABSENCE, MYOCLONIC, ATONIC
adults and children >4 y w/ partial seizures
adults and children > 6 y w/ primary generalized seizures--TONIC CLONIC
adults and children > 12 y w/ myoclonic seizures
Side Effects: somnolence, dizziness, weakness, irritability but not life-threatening. Few drug-drug interactions (not metabolized by CP450)
MOA: selective binding to synaptic vesicular protein SV2A (may modify synaptic release of glutamate, GABA)
|
|
|
Term
|
Definition
DOC for PARTIAL, including some secondary generalized seizures
Side Effects: rashes w/ high doses (Stephen Johnson). Asians at risk for severe skin rashes (test for HLA-B1502 in advance)
CNS (drowsiness, headache, decreased cognitive function)
mild leukopenia, hyponatremia
many drug-drug interactions
MOA: may reduce polysynaptic responses and block post-tetanic potentiation. Treat chronic pain of trigeminal neuralgia and diabetic neuropathy. |
|
|
Term
|
Definition
DOC for PARTIAL, including secondary generalized seizures
may WORSEN some patients with ABSENCE absence
Side Effects: Rashes, esp w/ hi doses, Asians at risk for severe skin rashes (test for HLA-B1502 in advance). CNS (drowsiness, headache, decreased cognitive function)
MOA: reduces polysynaptic responses and blocking post-tetanic potentiation. Also used to treat chronic pain of trigeminal neuralgia and diabetic neuropathy |
|
|
Term
|
Definition
DOC for ABSENCE (Petit Mal)
Side Effects: well tolerated (nausea, vomiting, hiccups)
MOA: ?
|
|
|
Term
pheytoin (formerly dipheylhydantoin) |
|
Definition
second-line drug, previously DOC for generalized tonic-clonic and partial seizures
Side Effects: complicated pharmacokinetics. Nystagmus, drowsiness, ataxia, diplopia, rash/hypersensitivity, gingival hyperplasia
MOA: may block sodium channels (stabilize threshold against hyperexcitability). Blocks calcium channels. May enhance GABA. |
|
|
Term
|
Definition
combination Rx, chronic pain syndromes
Side effects: few drug-drug interactions |
|
|
Term
|
Definition
adjunctive theapy for variety of seizures
phophylactic for migraines
treatment for neuropathic pain
Side Effects: paresthesisas, cognitive impairment; chronic use may cause metabolic acidosis, increasing risk of renal calculi
MOA: carbonic anhydrase inhibitor |
|
|
Term
diazepam (see benzodiazepines)
single-dose prefilled syringes
Diastat: new rectal formulation |
|
Definition
repetitive seizures (rapidly absorbed, effective for acute seizures, can be used in combo with other antiepileptics)
may decrease ER visits
Side Effects: ? make seizures worse
MOA:
|
|
|
Term
ginkgo biloba (see herbals) |
|
Definition
Natural Standard A grade for dementia
B grade for cerebral insufficiency
Side Effects: bleeding as montherapy, in combo
MOA: |
|
|
Term
|
Definition
B for improving mental performance
Side Effects: bleeding as monotherapy and combo, care when combo with cardiac drugs
|
|
|